BioAge Labs Chief Medical Officer Paul D. Rubin Exercises Options and Sells Shares Under 10b5-1 Plan

This Form 4 filing reports that Paul D. Rubin, Chief Medical Officer of BioAge Labs, Inc. (BIOA), executed significant stock transactions on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. Rubin exercised two sets of stock options: 5,437 shares at $4.11 per share and 3,383 shares at $6.57 per share, both of which were fully vested. Immediately following the exercises, he sold all 8,820 shares at $17.81 per share, resulting in a complete disposition of his direct holdings. The transactions were executed pursuant to a trading plan adopted on November 5, 2024. The filing indicates Rubin no longer holds any direct common stock in BioAge Labs following these transactions.